Asthma Classification and external resources
Peak flow meters are used to measure one's peak expiratory flow rate
ICD-10 J45 ICD-9 493 OMIM 600807 DiseasesDB 1006 MedlinePlus 000141 eMedicine article/806890 MeSH D001249
Asthma (from the Greek άσθμα, ásthma, "panting") is the common chronic inflammatory disease of the airways characterized by variable and recurring symptoms, reversible airflow obstruction, and bronchospasm. Symptoms include wheezing, coughing, chest tightness, and shortness of breath. Asthma is clinically classified according to the frequency of symptoms, forced expiratory volume in 1 second (FEV1), and peak expiratory flow rate. Asthma may also be classified as atopic (extrinsic) or non-atopic (intrinsic).
It is thought to be caused by a combination of genetic and environmental factors. Treatment of acute symptoms is usually with an inhaled short-acting beta-2 agonist (such as salbutamol). Symptoms can be prevented by avoiding triggers, such as allergens and irritants, and by inhaling corticosteroids. Leukotriene antagonists are less effective than corticosteroids and thus less preferred.
Its diagnosis is usually made based on the pattern of symptoms and/or response to therapy over time. The prevalence of asthma has increased significantly since the 1970s. As of 2010, 300 million people were affected worldwide. In 2009 asthma caused 250,000 deaths globally. Despite this, with proper control of asthma with step down therapy, prognosis is generally good.
- 1 Classification
- 2 Signs and symptoms
- 3 Causes
- 4 Diagnosis
- 5 Prevention
- 6 Management
- 7 Prognosis
- 8 Epidemiology
- 9 History
- 10 References
- 11 External links
Asthma is defined by the Global Initiative for Asthma as "a chronic inflammatory disorder of the airways in which many cells and cellular elements play a role. The chronic inflammation is associated with airway hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness and coughing particularly at night or in the early morning. These episodes are usually associated with widespread, but variable airflow obstruction within the lung that is often reversible either spontaneously or with treatment".
Clinical classification of severity Severity in patients ≥ 12 years of age  Symptom frequency Night time symptoms %FEV1 of predicted FEV1 Variability Use of short-acting beta2 agonist for symptom control (not for prevention of EIB) Intermittent ≤2 per week ≤2 per month ≥80% <20% ≤2 days per week Mild persistent >2 per week
but not daily
3-4 per month ≥80% 20–30% >2 days/week
but not daily
Moderate persistent Daily >1 per week but not nightly 60–80% >30% Daily Severe persistent Throughout the day Frequent (often 7x/week) <60% >30% Several times per day
Asthma is clinically classified according to the frequency of symptoms, forced expiratory volume in 1 second (FEV1), and peak expiratory flow rate. Asthma may also be classified as atopic (extrinsic) or non-atopic (intrinsic), based on whether symptoms are precipitated by allergens (atopic) or not (non-atopic).
While asthma is classified based on severity, at the moment there is no clear method for classifying different subgroups of asthma beyond this system. Within the classifications described above, although the cases of asthma respond to the same treatment differs, thus it is clear that the cases within a classification have significant differences. Finding ways to identify subgroups that respond well to different types of treatments is a current critical goal of asthma research.
Although asthma is a chronic obstructive condition, it is not considered as a part of chronic obstructive pulmonary disease as this term refers specifically to combinations of disease that are irreversible such as bronchiectasis, chronic bronchitis, and emphysema. Unlike these diseases, the airway obstruction in asthma is usually reversible; however, if left untreated, the chronic inflammation of the lungs during asthma can become irreversible obstruction due to airway remodeling. In contrast to emphysema, asthma affects the bronchi, not the alveoli.
Brittle asthma is a term used to describe two types of asthma, distinguishable by recurrent, severe attacks. Type 1 brittle asthma refers to disease with wide peak flow variability, despite intense medication. Type 2 brittle asthma describes background well-controlled asthma, with sudden severe exacerbations.
An acute asthma exacerbation is commonly referred to as an asthma attack. The classic symptoms are shortness of breath, wheezing, and chest tightness. While these are the primary symptoms of asthma, some people present primarily with coughing, and in severe cases, air motion may be significantly impaired such that no wheezing is heard.
Signs which occur during an asthma attack include the use of accessory muscles of respiration (sternocleidomastoid and scalene muscles of the neck), there may be a paradoxical pulse (a pulse that is weaker during inhalation and stronger during exhalation), and over-inflation of the chest. A blue color of the skin and nails may occur from lack of oxygen.
In a mild exacerbation the peak expiratory flow rate (PEFR) is ≥200 L/min or ≥50% of the predicted best. Moderate is defined as between 80 and 200 L/min or 25% and 50% of the predicted best while severe is defined as ≤ 80 L/min or ≤25% of the predicted best.
Insufficient levels of vitamin D are linked with severe asthma attacks.
Status asthmaticus is an acute exacerbation of asthma that does not respond to standard treatments of bronchodilators and steroids. Nonselective beta blockers (such as Timolol) have caused fatal status asthmaticus.
A diagnosis of asthma is common among top athletes. One survey of participants in the 1996 Summer Olympic Games, in Atlanta, Georgia, U.S., showed that 15% had been diagnosed with asthma, and that 10% were on asthma medication.
There appears to be a relatively high incidence of asthma in sports such as cycling, mountain biking, and long-distance running, and a relatively lower incidence in weightlifting and diving. It is unclear how much of these disparities are from the effects of training in the sport.
Exercise induced asthma can be treated with the use of a short-acting beta2 agonist.
Asthma as a result of (or worsened by) workplace exposures is a commonly reported occupational respiratory disease. Still most cases of occupational asthma are not reported or are not recognized as such. Estimates by the American Thoracic Society (2004) suggest that 15–23% of new-onset asthma cases in adults are work related. In one study monitoring workplace asthma by occupation, the highest percentage of cases occurred among operators, fabricators, and laborers (32.9%), followed by managerial and professional specialists (20.2%), and in technical, sales, and administrative support jobs (19.2%). Most cases were associated with the manufacturing (41.4%) and services (34.2%) industries. Animal proteins, enzymes, flour, natural rubber latex, and certain reactive chemicals are commonly associated with work-related asthma. When recognized, these hazards can be mitigated, dropping the risk of disease.
Signs and symptoms
Common symptoms of asthma include wheezing, shortness of breath, chest tightness and coughing, and use of accessory muscle. Symptoms are often worse at night or in the early morning, or in response to exercise or cold air. Some people with asthma only rarely experience symptoms, usually in response to triggers, whereas other may have marked persistent airflow obstruction.
Gastro-esophageal reflux disease
Gastro-esophageal reflux disease coexists with asthma in 80% of people with asthma, with similar symptoms. Various theories say that asthma could facilitate GERD and/or viceversa. The first case could be due to the effect of change in thoracic pressures, use of antiasthma drugs, could facilitate the passage of the gastric content back into the oesophagus by increasing abdominal pressure or decreasing the lower esophageal sphincter. The second by promoting bronchoconstriction and irritation by chronic acid aspiration, vagally mediated reflexes and others factors that increase bronchial responsiveness and irritation.
Due to altered anatomy of the respiratory tract: increased upper airway adipose deposition, altered pharynx skeletal morphology, and extension of the pharyngeal airway; leading to upper airway collapse.
Asthma is caused by environmental and genetic factors. These factors influence how severe asthma is and how well it responds to medication. The interaction is complex and not fully understood.
Studying the prevalence of asthma and related diseases such as eczema and hay fever have yielded important clues about some key risk factors. The strongest risk factor for developing asthma is a history of atopic disease; this increases one's risk of hay fever by up to 5x and the risk of asthma by 3-4x. In children between the ages of 3-14, a positive skin test for allergies and an increase in immunoglobulin E increases the chance of having asthma. In adults, the more allergens one reacts positively to in a skin test, the higher the odds of having asthma.
Because much allergic asthma is associated with sensitivity to indoor allergens and because Western styles of housing favor greater exposure to indoor allergens, much attention has focused on increased exposure to these allergens in infancy and early childhood as a primary cause of the rise in asthma. Primary prevention studies aimed at the aggressive reduction of airborne allergens in a home with infants have shown mixed findings. Strict reduction of dust mite allergens, for example, reduces the risk of allergic sensitization to dust mites, and modestly reduces the risk of developing asthma up until the age of 8 years old. However, studies also showed that the effects of exposure to cat and dog allergens worked in the converse fashion; exposure during the first year of life was found to reduce the risk of allergic sensitization and of developing asthma later in life.
The inconsistency of this data has inspired research into other facets of Western society and their impact upon the prevalence of asthma. One subject that appears to show a strong correlation is the development of asthma and obesity. In the United Kingdom and United States, the rise in asthma prevalence has echoed an almost epidemic rise in the prevalence of obesity. In Taiwan, symptoms of allergies and airway hyper-reactivity increased in correlation with each 20% increase in body-mass index. Several factors associated with obesity may play a role in the pathogenesis of asthma, including decreased respiratory function due to a buildup of adipose tissue (fat) and the fact that adipose tissue leads to a pro-inflammatory state, which has been associated with non-eosinophilic asthma.
Asthma has been associated with Churg–Strauss syndrome, and individuals with immunologically mediated urticaria may also experience systemic symptoms with generalized urticaria, rhino-conjunctivitis, orolaryngeal and gastrointestinal symptoms, asthma, and, at worst, anaphylaxis. Additionally, adult-onset asthma has been associated with periocular xanthogranulomas.
Many environmental risk factors have been associated with asthma development and morbidity in children. Recent studies show a relationship between exposure to air pollutants (e.g. from traffic) and childhood asthma. This research finds that both the occurrence of the disease and exacerbation of childhood asthma are affected by outdoor air pollutants. High levels of endotoxin exposure may contribute to asthma risk.
Psychological stress has long been suspected of being an asthma trigger, but only in recent decades has convincing scientific evidence substantiated this hypothesis. Rather than stress directly causing the asthma symptoms, it is thought that stress modulates the immune system to increase the magnitude of the airway inflammatory response to allergens and irritants.
Maternal tobacco smoking during pregnancy and after delivery is associated with a greater risk of asthma-like symptoms, wheezing, and respiratory infections during childhood. Low air quality, from traffic pollution or high ozone levels, has been repeatedly associated with increased asthma morbidity and has a suggested association with asthma development that needs further research.
Antibiotic use early in life has been linked to development of asthma in several examples; it is thought that antibiotics make children who are predisposed to atopic immune responses susceptible to development of asthma because they modify gut flora, and thus the immune system (as described by the hygiene hypothesis). The hygiene hypothesis (see below) is a hypothesis about the cause of asthma and other allergic disease, and is supported by epidemiologic data for asthma. All of these things may negatively affect exposure to beneficial bacteria and other immune system modulators that are important during development, and thus may cause an increased risk for asthma and allergy.
Volatile organic compounds
Observational studies have found that indoor exposure to volatile organic compounds (VOCs) may be one of the triggers of asthma, however experimental studies have not confirmed these observations. Even VOC exposure at low levels has been associated with an increase in the risk of pediatric asthma. Because there are so many VOCs in the air, measuring total VOC concentrations in the indoor environment may not represent the exposure of individual compounds. Exposure to VOCs is associated with an increase in the IL-4 producing Th2 cells and a reduction in IFN-γ producing Th1 cells. Thus the mechanism of action of VOC exposure may be allergic sensitization mediated by a Th2 cell phenotype. Different individual variations in discomfort, from no response to excessive response, were seen in one of the studies. These variations may be due to the development of tolerance during exposure. Another study has concluded that formaldehyde may cause asthma-like symptoms. Low VOC emitting materials should be used while doing repairs or renovations which decreases the symptoms related to asthma caused by VOCs and formaldehyde. In another study "the indoor concentration of aliphatic compounds (C8-C11), butanols, and 2,2,4-trimethyl 1,3-pentanediol diisobutyrate (TXIB) was significantly elevated in newly painted dwellings. The total indoor VOC was about 100 micrograms/m3 higher in dwellings painted in the last year". The author concluded that some VOCs may cause inflammatory reactions in the airways and may be the reason for asthmatic symptoms.
Gas cooking stoves have emissions of Carbon monoxide, CO2, NO2, NO, aldehydes, RSP, and other VOC’s. The exposure concentration of NO2 is 18-35 ppbv, These numbers are significantly high and can had adverse effects on asthma. The inhalation of NO2 has an increased risk of respiratory symptoms and can change the lung function in children. According to the United States Environmental Protection Agency it is significantly important to use the exhaust fan when cooking with gas stoves to eliminate as many VOC’s as possible.
There is a significant association between asthma-like symptoms (wheezing) among preschool children and the concentration of DEHP (phthalates) in indoor environment. DEHP (di-ethylhexyl phthalate) is a plasticizer that is commonly used in building material. The hydrolysis product of DEHP (di-ethylhexyl phthalate) is MEHP (Mono-ethylhexyl phthalate) which mimics the prostaglandins and thromboxanes in the airway leading to symptoms related to asthma. Another mechanism that has been studied regarding phthalates causation of asthma is that high phthalates level can "modulate the murine immune response to a coallergen". Asthma can develop in the adults who come in contact with heated PVC fumes. Two main type of phthalates, namely n-butyl benzyl phthalate (BBzP) and di(2-ethylhexyl) phthalate (DEHP), have been associated between the concentration of polyvinyl chloride (PVC) used as flooring and the dust concentrations. Water leakage were associated more with BBzP, and buildings construction were associated with high concentrations of DEHP. Asthma has been shown to have a relationship with plaster wall materials and wall-to wall carpeting. The onset of asthma was also related to the floor–leveling plaster at home. Therefore, it is important to understand the health aspect of these materials in the indoor surfaces.
Over 100 genes have been associated with asthma in at least one genetic association study. However, such studies must be repeated to ensure the findings are not due to chance. Through the end of 2005, 25 genes had been associated with asthma in six or more separate populations:
Many of these genes are related to the immune system or to modulating inflammation. However, even among this list of highly replicated genes associated with asthma, the results have not been consistent among all of the populations that have been tested. This indicates that these genes are not associated with asthma under every condition, and that researchers need to do further investigation to figure out the complex interactions that cause asthma. One theory is that asthma is a collection of several diseases, and that genes might have a role in only subsets of asthma. For example, one group of genetic differences (single nucleotide polymorphisms in 17q21) was associated with asthma that develops in childhood.
CD14-endotoxin interaction based on CD14 SNP C-159T Endotoxin levels CC genotype TT genotype High exposure Low risk High risk Low exposure High risk Low risk
Research suggests that some genetic variants may only cause asthma when they are combined with specific environmental exposures, and otherwise may not be risk factors for asthma.
The genetic trait, CD14 single nucleotide polymorphism (SNP) C-159T and exposure to endotoxin (a bacterial product) are a well-replicated example of a gene-environment interaction that is associated with asthma. Endotoxin exposure varies from person to person and can come from several environmental sources, including environmental tobacco smoke, dogs, and farms. Researchers have found that risk for asthma changes based on a person's genotype at CD14 C-159T and level of endotoxin exposure.
Some individuals will have stable asthma for weeks or months and then suddenly develop an episode of acute asthma. Different asthmatic individuals react differently to various factors. However, most individuals can develop severe exacerbation of asthma from several triggering agents.
Home factors that can lead to exacerbation include dust, house mites, animal dander (especially cat and dog hair), cockroach allergens and molds at any given home. Perfumes are a common cause of acute attacks in females and children. Both virus and bacterial infections of the upper respiratory tract infection can worsen asthma.
One theory for the cause of the increase in asthma prevalence worldwide is the "hygiene hypothesis" —that the rise in the prevalence of allergies and asthma is a direct and unintended result of reduced exposure to a wide variety of different bacteria and virus types in modern societies, or modern hygienic practices preventing childhood infections. Children living in less hygienic environments (East Germany vs. West Germany, families with many children, day care environments) tend to have lower incidences of asthma and allergic diseases. This seems to run counter to the logic that viruses are often causative agents in exacerbation of asthma. Additionally, other studies have shown that viral infections of the lower airway may in some cases induce asthma, as a history of bronchiolitis or croup in early childhood is a predictor of asthma risk in later life. Studies which show that upper respiratory tract infections are protective against asthma risk also tend to show that lower respiratory tract infections conversely tend to increase the risk of asthma.
The incidence of asthma is highest among low-income populations worldwide[specify]. Asthma deaths are most common in low and middle income countries, and in the Western world, it is found in those low-income neighborhoods whose populations consist of large percentages of ethnic minorities. Additionally, asthma has been strongly associated with the presence of cockroaches in living quarters; these insects are more likely to be found in those same neighborhoods.
Most likely due to income and geography, the incidence of and treatment quality for asthma varies among different racial groups. The prevalence of "severe persistent" asthma is also greater in low-income communities than those with better access to treatment.
Severity of acute asthma exacerbations Near-fatal asthma High PaCO2 and/or requiring mechanical ventilation Life threatening asthma Any one of the following in a person with severe asthma:- Clinical signs Measurements Altered level of consciousness Peak flow < 33% Exhaustion Oxygen saturation < 92% Arrhythmia PaO2 < 8 kPa Low blood pressure "Normal" PaCO2 Cyanosis Silent chest Poor respiratory effort Acute severe asthma Any one of:- Peak flow 33-50% Respiratory rate ≥ 25 breaths per minute Heart rate ≥ 110 beats per minute Unable to complete sentences in one breath Moderate asthma exacerbation Worsening symptoms Peak flow 80%-50% best or predicted No features of acute severe asthma
There is currently not a precise physiologic, immunologic, or histologic test for diagnosing asthma. The diagnosis is usually made based on the pattern of symptoms (airways obstruction and hyperresponsiveness) and/or response to therapy (partial or complete reversibility) over time.
The British Thoracic Society determines a diagnosis of asthma using a ‘response to therapy’ approach. If the patient responds to treatment, then this is considered to be a confirmation of the diagnosis of asthma. The response measured is the reversibility of airway obstruction after treatment. Airflow in the airways is measured with a peak flow meter or spirometer, and the following diagnostic criteria are used by the British Thoracic Society:
- ≥20% difference on at least three days in a week for at least two weeks;
- ≥20% improvement of peak flow following treatment, for example:
- ≥20% decrease in peak flow following exposure to a trigger (e.g., exercise).
In contrast, the US National Asthma Education and Prevention Program (NAEPP) uses a ‘symptom patterns’ approach. Their guidelines for the diagnosis and management of asthma state that a diagnosis of asthma begins by assessing if any of the following list of indicators is present. While the indicators are not sufficient to support a diagnosis of asthma, the presence of multiple key indicators increases the probability of a diagnosis of asthma. Spirometry is needed to establish a diagnosis of asthma.
- Wheezing—high-pitched whistling sounds when breathing out—especially in children. (Lack of wheezing and a normal chest examination do not exclude asthma.)
- history of any of the following:
- Cough, worse particularly at night
- Recurrent wheeze
- Recurrent difficulty in breathing
- Recurrent chest tightness
- Symptoms occur or worsen in the presence of:
- Viral infection
- Animals with fur or hair
- House-dust mites (in mattresses, pillows, upholstered furniture, carpets)
- Smoke (tobacco, wood)
- Changes in weather
- Strong emotional expression (laughing or crying hard)
- Airborne chemicals or dusts
- Menstrual cycles
- Symptoms occur or worsen at night, awakening the patient
The latest guidelines from the U.S. National Asthma Education and Prevention Program (NAEPP) recommend spirometry at the time of initial diagnosis, after treatment is initiated and symptoms are stabilized, whenever control of symptoms deteriorates, and every 1 or 2 years on a regular basis. The NAEPP guidelines do not recommend testing peak expiratory flow as a regular screening method because it is more variable than spirometry. However, testing peak flow at rest (or baseline) and after exercise can be helpful, especially in young patients who may experience only exercise-induced asthma. It may also be useful for daily self-monitoring and for checking the effects of new medications. Peak flow readings can be charted together with a record of symptoms or use peak flow charting software. This allows patients to track their peak flow readings and pass information back to their doctor or respiratory therapist.
Differential diagnoses include:
- Infants and Children
- Upper airway diseases
- Allergic rhinitis and allergic sinusitis
- Obstructions involving large airways
- Obstructions involving small airways
- Other causes
- Recurrent cough not due to asthma
- Aspiration from swallowing mechanism dysfunction or gastroesophageal reflux
- Medication induced
- Upper airway diseases
- COPD (e.g., chronic bronchitis or emphysema)
- Congestive heart failure
- Pulmonary embolism
- Mechanical obstruction of the airways (benign and malignant tumors)
- Pulmonary infiltration with eosinophilia
- Cough secondary to drugs (e.g., angiotensin-converting enzyme (ACE) inhibitors)
- Vocal cord dysfunction
Before diagnosing asthma, alternative possibilities should be considered such as the use of known bronchoconstrictors (substances that cause narrowing of the airways, e.g. certain anti-inflammatory agents or beta-blockers). Among elderly people, the presenting symptom may be fatigue, cough, or difficulty breathing, all of which may be erroneously attributed to Chronic obstructive pulmonary disease(COPD), congestive heart failure, or simple aging.
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease can coexist with asthma and can occur as a complication of chronic asthma. After the age of 65 most people with obstructive airway disease will have asthma and COPD. In this setting, COPD can be differentiated by increased airway neutrophils, abnormally increased wall thickness, and increased smooth muscle in the bronchi. However, this level of investigation is not performed due to COPD and asthma sharing similar principles of management: corticosteroids, long acting beta agonists, and smoking cessation. It closely resembles asthma in symptoms, is correlated with more exposure to cigarette smoke, an older age, less symptom reversibility after bronchodilator administration (as measured by spirometry), and decreased likelihood of family history of atopy.
The term "atopy" was coined to describe this triad of atopic eczema, allergic rhinitis and asthma.
Pulmonary aspiration, whether direct due to dysphagia (swallowing disorder) or indirect (due to acid reflux), can show similar symptoms to asthma. However, with aspiration, fevers might also indicate aspiration pneumonia. Direct aspiration (dysphagia) can be diagnosed by performing a modified barium swallow test. If the aspiration is indirect (from acid reflux), then treatment is directed at this is indicated.
The evidence for the effectiveness of measures to prevent the development of asthma is weak. Ones which show some promise include limiting smoke exposure both in utero and after delivery, breastfeeding, increased exposure to respiratory infection per the hygiene hypothesis (such as in those who attend daycare or are from large families).
A specific, customized plan for proactively monitoring and managing symptoms should be created. Someone who has asthma should understand the importance of reducing exposure to allergens, testing to assess the severity of symptoms, and the usage of medications. The treatment plan should be written down and adjusted according to changes in symptoms.
The most effective treatment for asthma is identifying triggers, such as cigarette smoke, pets, or aspirin, and eliminating exposure to them. If trigger avoidance is insufficient, medical treatment is recommended. Medical treatments used depend on the severity of illness and the frequency of symptoms. Specific medications for asthma are broadly classified into fast-acting and long-acting categories.
Bronchodilators are recommended for short-term relief of symptoms. In those with occasional attacks, no other medication is needed. If mild persistent disease is present (more than two attacks a week), low-dose inhaled glucocorticoids or alternatively, an oral leukotriene antagonist or a mast cell stabilizer is recommended. For those who suffer daily attacks, a higher dose of inhaled glucocorticoid is used. In a severe asthma exacerbation, oral glucocorticoids are added to these treatments.
Avoidance of triggers is a key component of improving control and preventing attacks. The most common triggers include allergens, smoke (tobacco and other), air pollution, non selective beta-blockers, and sulfite-containing foods.
Medications used to treat asthma are divided into two general classes: quick-relief medications used to treat acute symptoms; and long-term control medications used to prevent further exacerbation.
- Fast acting
- Short acting beta2-adrenoceptor agonists (SABA), such as salbutamol (albuterol USAN) are the first line treatment for asthma symptoms.
- Anticholinergic medications, such as ipratropium bromide, provide additional benefit when used in combination with SABA in those with moderate or severe symptoms. Anticholinergic bronchodilators can also be used if a person cannot tolerate a SABA.
- Older, less selective adrenergic agonists, such as inhaled epinephrine, have similar efficacy to SABAs. They are however not recommended due to concerns regarding excessive cardiac stimulation.
- Long term control
- Glucocorticoids are the most effective treatment available for long term control. Inhaled forms are usually used except in the case of severe persistent disease, in which oral steroids may be needed. Inhaled formulations may be used once or twice daily, depending on the severity of symptoms.
- Long acting beta-adrenoceptor agonists (LABA) have at least a 12-hour effect. They are however not to be used without a steroid due to an increased risk of severe symptoms. In December 2008, members of the FDA's drug-safety office recommended withdrawing approval for these medications in children. Discussion is ongoing about their use in adults.
- Leukotriene antagonists (such as zafirlukast) are an alternative to inhaled glucocorticoids, but are not preferred. They may also be used in addition to inhaled glucocorticoids but in this role are second line to LABA.
- Mast cell stabilizers (such as cromolyn sodium) are another non-preferred alternative to glucocorticoids.
- Delivery methods
Medications are typically provided as metered-dose inhalers (MDIs) in combination with an asthma spacer or as a dry powder inhaler. The spacer is a plastic cylinder that mixes the medication with air, making it easier to receive a full dose of the drug. A nebulizer may also be used. Nebulizers and spacers are equally effective in those with mild to moderate symptoms however insufficient evidence is available to determine whether or not a difference exists in those severe symptomatology.
- Safety and adverse effects
Long-term use of glucocorticoids carries a significant potential for adverse effects. The incidence of cataracts is increased in people undergoing treatment for asthma with corticosteroids, due to altered regulation of lens epithelial cells. The incidence of osteoporosis is also increased, due to changes in bone remodeling.
When asthma is unresponsive to usual medications, other options are available for both emergency management and prevention of flairs. For emergency management other options include:
- Oxygen is used to alleviate hypoxia if saturations fall below 92%.
- Magnesium sulfate intravenous treatment has been shown to provide a bronchodilating effect when used in addition to other treatment in severe acute asthma attacks.
- Heliox, a mixture of helium and oxygen, may also be considered in severe unresponsive cases.
- Intravenous salbutamol is not supported by available evidence and is thus used only in extreme cases.
- Methylxanthines (such as theophylline) were once widely used, but do not add significantly to the effects of inhaled beta-agonists.
- The dissociative anesthetic ketamine is theoretically useful if intubation and mechanical ventilation is needed in people who are approaching respiratory arrest; however, there is no evidence from clinical trials to support this.
For those with severe persistent asthma not controlled by inhaled corticosteroids and LABAs bronchial thermoplasty can lead to clinical improvements. It involves the delivery of controlled thermal energy to the airway wall during a series of bronchoscopies and result in a prolonged reduction in airway smooth muscle mass.
Many people with asthma, like those who suffer from other chronic disorders, use alternative treatments; surveys show that roughly 50% of asthma patients use some form of unconventional therapy. There is little data to support the effectiveness of most of these therapies. Evidence is insufficient to support the usage of Vitamin C. Acupuncture is not recommended for the treatment as there is insufficient evidence to support its use. Air ionisers show no evidence that they improve asthma symptoms or benefit lung function; this applied equally to positive and negative ion generators.
Dust mite control measures, including air filtration, chemicals to kill mites, vacuuming, mattress covers and others methods had no effect on asthma symptoms. However, a review of 30 studies found that "bedding encasement might be an effective asthma treatment under some conditions" (when the patient is highly allergic to dust mite and the intervention reduces the dust mite exposure level from high levels to low levels). Washing laundry/rugs in hot water was also found to improve control of allergens.
A study of "manual therapies" for asthma, including osteopathic, chiropractic, physiotherapeutic and respiratory therapeutic manoeuvres, found there is insufficient evidence to support their use in treating. The Buteyko breathing technique for controlling hyperventilation may result in a reduction in medications use however does not have any effect on lung function. Thus an expert panel felt that evidence was insufficient to support its use.
The prognosis for asthma is good, especially for children with mild disease.[not in citation given] Of asthma diagnosed during childhood, 54% of cases will no longer carry the diagnosis after a decade. The extent of permanent lung damage in people with asthma is unclear. Airway remodeling is observed, but it is unknown whether these represent harmful or beneficial changes. Although conclusions from studies are mixed, most studies show that early treatment with glucocorticoids prevents or ameliorates decline in lung function as measured by several parameters. For those who continue to suffer from mild symptoms, corticosteroids can help most to live their lives with few disabilities. It is more likely to consider immediate medication of inhaled corticosteroids as soon as asthma attacks occur. According to studies conducted, patients with relatively mild asthma who have received inhaled corticosteroids within 12 months of their first asthma symptoms achieved good functional control of asthma after 10 years of individualized therapy as compared to patients who received this medication after 2 years (or more) from their first attacks. Though they (delayed) also had good functional control of asthma, they were observed to exhibit slightly less optimal disease control and more signs of airway inflammation.
Asthma mortality has decreased over the last few decades due to better recognition and improvement in care.
It is estimated that asthma has a 7-10% prevalence worldwide. As of 1998, there was a great disparity in the prevalence of asthma across the world, with a trend toward more developed and westernized countries having higher rates of asthma, with as high as a 20 to 60-fold difference. Westernization however does not explain the entire difference in asthma prevalence between countries, and the disparities may also be affected by differences in genetic, social and environmental risk factors. Mortality however is most common in low to middle income countries, while symptoms were most prevalent (as much as 20%) in the United Kingdom, Australia, New Zealand, and Republic of Ireland; they were lowest (as low as 2–3%) in Eastern Europe, Indonesia, Greece, Uzbekistan, India, and Ethiopia.[dated info]
While asthma is more common in affluent countries, it is by no means a restricted problem; the WHO estimate that there are between 15 and 20 million people with asthma in India. In the U.S., urban residents, Hispanics, and African Americans are affected more than the population as a whole. Striking increases in asthma prevalence have been observed in populations migrating from a rural environment to an urban one,[dated info] or from a third-world country to Westernized one.[dated info]
Asthma affects approximately 7% of the population of the United States and 5% of people in the United Kingdom. Asthma causes 4,210 deaths per year in the United States. In 2005 in the United States asthma affected more than 22 million people including 6 million children. It accounted for nearly 1/2 million hospitalizations that same year. More boys have asthma than girls, but more women have it than men. Of all children, African Americans and Latinos who live in cities are more at risk for developing asthma. African American children in the U.S. are four times more likely to die of asthma and three times more likely to be hospitalized, compared to their white counterparts. In some Latino neighborhoods, as many as one in three children has been found to have asthma.
In England, an estimated 261,400 people were newly diagnosed with asthma in 2005; 5.7 million people had an asthma diagnosis and were prescribed 32.6 million asthma-related prescriptions.
Rates of asthma have increased significantly between the 1960s and 2008. Some 9% of US children had asthma in 2001, compared with just 3.6% in 1980. The World Health Organization (WHO) reports that some 10% of the Swiss population suffers from asthma today, compared with just 2% some 25–30 years ago. In the United States specifically data from several national surveys in the United States reveal the age-adjusted prevalence of asthma increased from 7.3 to 8.2 percent during the years 2001 through 2009 . Previous analysis of data from 2001 to 2007 had suggested the prevalence of asthma was stable.
Asthma prevalence in the US is higher than in most other countries in the world, but varies drastically between diverse US populations. In the US, asthma prevalence is highest in Puerto Ricans, African Americans, Filipinos, Irish Americans, and Native Hawaiians, and lowest in Mexicans and Koreans. Mortality rates follow similar trends, and response to salbutamol is lower in Puerto Ricans than in African Americans or Mexicans. As with worldwide asthma disparities, differences in asthma prevalence, mortality, and drug response in the US may be explained by differences in genetic, social and environmental risk factors.
Asthma prevalence also differs between populations of the same ethnicity who are born and live in different places. US-born Mexican populations, for example, have higher asthma rates than non-US born Mexican populations that are living in the US.
There is no correlation between asthma and gender in children. More adult women are diagnosed with asthma than adult men, but this does not necessarily mean that more adult women have asthma.
Asthma was first recognized and named by Hippocrates circa 450 BC. During the 1930s–50s, asthma was considered as being one of the 'holy seven' psychosomatic illnesses. Its aetiology was considered to be psychological, with treatment often based on psychoanalysis and other 'talking cures'. As these psychoanalysts interpreted the asthmatic wheeze as the suppressed cry of the child for its mother, so they considered that the treatment of depression was especially important for individuals with asthma. among the first papers in modern medicine, is one that was published in 1873 and this paper tried to explain the pathophysiology of the disease. And one of the first papers discussing treatment of asthma was released in 1872, the author concluded in his paper that asthma can be cured by rubbing the chest with chloroform liniment. Among the first times researchers referred to medical treatment was in 1880, when Dr. J. B. Berkart used IV therapy to administer doses of a drug called pilocarpin. In 1886, F.H. Bosworth FH suspected a connection between asthma and hay fever. Epinephrine was first referred to in the treatment of asthma in 1905, and for acute asthma in 1910.
- ^ NHLBI 2007 p.11–12
- ^ BTS 2009 p.3
- ^ a b c Yawn, BP (September 2008). "Factors accounting for asthma variability: achieving optimal symptom control for individual patients". Primary Care Respiratory Journal 17 (3): 138–147. doi:10.3132/pcrj.2008.00004. PMID 18264646. http://www.thepcrj.org/journ/vol17/17_3_138_147.pdf.
- ^ a b Kumar, Vinay; Abbas, Abul K; Fausto, Nelson; Aster, Jon (2010). Robbins and Cotran Pathologic Basis of Disease (8th ed.). Saunders. p. 688. ISBN 9781416031215.
- ^ a b c Martinez FD (2007). "Genes, environments, development and asthma: a reappraisal". Eur Respir J 29 (1): 179–84. doi:10.1183/09031936.00087906. PMID 17197483.
- ^ a b c NHLBI 2007 p.214
- ^ NHLBI 2007 p.169–172
- ^ GINA 2009 p.69
- ^ Fanta CH (March 2009). "Asthma". N Engl J Med 360 (10): 1002–14. doi:10.1056/NEJMra0804579. PMID 19264689.
- ^ a b Lemanske RF, Busse WW (February 2010). "Asthma: clinical expression and molecular mechanisms". J. Allergy Clin. Immunol. 125 (2 Suppl 2): S95–102. doi:10.1016/j.jaci.2009.10.047. PMC 2853245. PMID 20176271. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2853245.
- ^ http://www.ginasthma.org/Guidelineitem.asp??l1=2&l2=1&intId=37
- ^ a b GINA 2009 p.2
- ^ a b c Tippets B, Guilbert TW (2009). "Managing Asthma in Children: Part 1: Making the Diagnosis, Assessing Severity". Consultant for Pediatricians 8 (5). http://www.consultantlive.com/asthma/article/10162/1414747.
- ^ http://www.ginasthma.org/pdf/GINA_Report_2010.pdf
- ^ a b c d e f g Self, Timothy. Chrisman,Cary. Finch, Christopher. "Applied Therapeutics: The Clinical Use of Drugs, 9th Edition" Philadelphia: Lippincott Williams & Wilkins, 2009. Chapter 22 (Asthma)
- ^ a b c Moore WC, Pascual RM (June 2010). "Update in asthma 2009". American journal of respiratory and critical care medicine 181 (11): 1181–7. doi:10.1164/rccm.201003-0321UP. PMID 20516492.
- ^ Delacourt, C (June 2004). "Bronchial changes in untreated asthma". Archives de Pédiatrie 11 (Suppl. 2): 71s–73s. PMID 15301800.
- ^ Schiffman, George (18 December 2009). "Chronic Obstructive Pulmonary Disease". MedicineNet. http://www.medicinenet.com/chronic_obstructive_pulmonary_disease_copd/article.htm. Retrieved 2 September 2010.
- ^ a b c d BTS 2009 p.54
- ^ Mason, Robert J; Broaddus, V Courtney; Murray, John F; Nadel, Jay A (2005). "Asthma". Murray and Nadel's Textbook of Respiratory Medicine (4th ed.). Elsevier. ISBN 978-0721603278.
- ^ Barnes, PJ (2008). "Asthma". In Fauci, Anthony S; Braunwald, E,; Kasper, DL. Harrison's Principles of Internal Medicine (17th ed.). New York: McGraw-Hill. pp. 1596–1607. ISBN 9780071466332.
- ^ Abu-Hilal, MA; Mookadam, F (February 2010). "Pulsus paradoxus; historical and clinical perspectives". International Journal of Cardiology 138 (3): 229–32. doi:10.1016/j.ijcard.2009.04.045. PMID 19464740.
- ^ Werner, HA (June 2001). "Status asthmaticus in children: a review". Chest 119 (6): 1596–1607. doi:10.1378/chest.119.6.1913. PMID 11399724. http://chestjournal.chestpubs.org/content/119/6/1913.long.
- ^ a b Shiber JR, Santana J (May 2006). "Dyspnea". Med. Clin. North Am. 90 (3): 453–79. doi:10.1016/j.mcna.2005.11.006. PMID 16473100.
- ^ "Insufficient vitamin D tied to severe asthma attacks". Reuters. 2010-06-23. http://www.reuters.com/article/idUSTRE65M5E920100623.
- ^ Dipiro J.T. Talbert R.L. Yee G.C. Matzke G.R. Wells B.G. Posey L.M., (2008). Pharmacotherpay. a pathophysiologic approach (7 ed.). pp. 524.
- ^ a b Weiler JM, Layton T, Hunt M (1998). "Asthma in United States Olympic athletes who participated in the 1996 Summer Games". J. Allergy Clin. Immunol. 102 (5): 722–6. doi:10.1016/S0091-6749(98)70010-7. PMID 9819287.
- ^ Helenius I, Haahtela T (2000). "Allergy and asthma in elite summer sport athletes". J. Allergy Clin. Immunol. 106 (3): 444–52. doi:10.1067/mai.2000.107749. PMID 10984362.
- ^ a b "Fatal and Nonfatal Injuries, and Selected Illnesses and Conditions: Respiratory Diseases". Worker Health Chartbook 2004. National Institute for Occupational Safety and Health. September 2004. http://www.cdc.gov/niosh/docs/2004-146/ch2/ch2-10.asp.htm. Retrieved December 17, 2008.
- ^ "Asthma and Allergies". National Institute for Occupational Safety and Health. September 22, 2008. http://www.cdc.gov/niosh/topics/asthma/. Retrieved March 23, 2009.
- ^ BTS 2009 p.12
- ^ GINA 2009 p.8–9
- ^ Boulet LP (April 2009). "Influence of comorbid conditions on asthma". Eur Respir J 33 (4): 897–906. doi:10.1183/09031936.00121308. PMID 19336592.
- ^ Harrington JJ, Lee-Chiong T (December 2007). "Sleep and older patients". Clin Chest Med 28 (4): 673–84, v. doi:10.1016/j.ccm.2007.07.002. PMID 17967287.
- ^ Choudhry S, Seibold MA, Borrell LN "et al." (2007). "Dissecting complex diseases in complex populations: asthma in latino americans". Proc Am Thorac Soc 4 (3): 226–33. doi:10.1513/pats.200701-029AW. PMC 2647623. PMID 17607004. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2647623.
- ^ Miller, RL; Ho SM (March 2008). "Environmental epigenetics and asthma: current concepts and call for studies". American Journal of Respiratory and Critical Care Medicine 177 (6): 567–573. doi:10.1164/rccm.200710-1511PP. PMC 2267336. PMID 18187692. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2267336.
- ^ GINA 2009, p.4
- ^ a b NHLBI 2007. p.11
- ^ Ronmark E, Lundback B, Jonsson EA, et al. (1997). "Incidence of asthma in adults: Report from the obstructive lung disease in northern Sweden study". Allergy 52 (11): 1071–81. doi:10.1111/j.1398-9995.1997.tb00178.x. PMID 9404558.
- ^ Burrows B, Martinez FD, Holonen M, et al. (1989). "Association of asthma with serum IgE levels and skin-test reactivity to allergens". N Engl J Med 320 (5): 271–7. doi:10.1056/NEJM198902023200502. PMID 2911321.
- ^ Simpson BM, Custovic A, Simpson A, et al.; NAC Manchester Asthma and Allergy Study (NACMAAS) (2001). "Risk factors for asthma and allergic disorders in adults". Clin Exp Allergy 31 (3): 391–9. doi:10.1046/j.1365-2222.2001.01050.x. PMID 11260150.
- ^ Peat JK, Tovey E, Toelle BG, et al. (1996). "House dust mite allergens: A major risk factor for childhood asthma in Australia". Am J Respir Crit Care Med 153 (1): 141–6. PMID 8542107.
- ^ Custovic A, Smith AC, Woodcock A: "Indoor allergens are a primary cause of asthma: Asthma and the environment." Eur Respir Rev 1998; 53:155-158.
- ^ Chan-Yeung M, Manfreda J, Dimich-Ward H, et al. (2000). "A randomized controlled study on the effectiveness of a multifaceted intervention program in the primary prevention of asthma in high-risk infants". Arch Pediatr Adolesc Med 154 (7): 657–663. PMID 10891016.
- ^ Custovic A, Simpson BM, Simpson A, et al. (2001). "Effect of environmental manipulation in pregnancy and early life on respiratory symptoms and atopy during first year of life: A randomised trial". Lancet 358 (9277): 188–193. doi:10.1016/S0140-6736(01)05406-X. PMID 11476835.
- ^ Arshad SH, Bojarskas J, Tsitoura S, et al. (2002). "Prevention of sensitization to house dust mite by allergen avoidance in school age children: A randomized controlled study". Clin Exp Allergy 32 (6): 843–9. doi:10.1046/j.1365-2222.2002.01378.x. PMID 12047429.
- ^ Arshad SH, Bateman B, Matthews SM (2003). "Primary prevention of asthma and atopy during childhood by allergen avoidance in infancy: A randomised controlled study". Thorax 58 (6): 489–493. doi:10.1136/thorax.58.6.489. PMC 1746711. PMID 12775858. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1746711.
- ^ Celedon JC, Litonjua AA, Ryan L, et al. (2002). "Exposure to cat allergen, maternal history of asthma, and wheezing in first 5 years of life". Lancet 360 (9335): 781–2. doi:10.1016/S0140-6736(02)09906-3. PMID 12241839.
- ^ Ownby DR, Johnson CC, Peterson EL (2002). "Exposure to dogs and cats in the first year of life and risk of allergic sensitization at 6 to 7 years of age". JAMA 288 (8): 963–972. doi:10.1001/jama.288.8.963. PMID 12190366.
- ^ Perzanowski MS, Ronmark E, Platts-Mills TA, Lundback B (2002). "Effect of cat and dog ownership on sensitization and development of asthma among preteenage children". Am J Respir Crit Care Med 166 (5): 696–702. doi:10.1164/rccm.2201035. PMID 12204868.
- ^ Beuther DA (January 2010). "Recent insight into obesity and asthma". Curr Opin Pulm Med 16 (1): 64–70. doi:10.1097/MCP.0b013e3283338fa7. PMID 19844182.
- ^ Holguin F, Fitzpatrick A (March 2010). "Obesity, asthma, and oxidative stress". J. Appl. Physiol. 108 (3): 754–9. doi:10.1152/japplphysiol.00702.2009. PMID 19926826.
- ^ Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL (1994). "Increasing prevalence of overweight among US adults: The National Health and Nutrition Examination Surveys, 1960–1991". JAMA 272 (3): 205–211. doi:10.1001/jama.272.3.205. PMID 8022039.
- ^ Troiano RP, Flegal KM, Kuczmarski RJ, et al. (1995). "Overweight prevalence and trends for children and adolescents: The National Health and Nutrition Examination Surveys, 1963–1991". Arch Pediatr Adolesc Med 149 (10): 1085–91. PMID 7550810.
- ^ Huang S-L, Shiao GM, Chou P (1998). "Association between body mass index and allergy in teenage girls in Taiwan". Clin Exp Allergy 29 (3): 323–9. PMID 10202338.
- ^ Wood LG, Gibson PG (July 2009). "Dietary factors lead to innate immune activation in asthma". Pharmacol. Ther. 123 (1): 37–53. doi:10.1016/j.pharmthera.2009.03.015. PMID 19375453.
- ^ a b c Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. ISBN 1-4160-2999-0.
- ^ Jakobiec FA, Mills MD, Hidayat AA, Dallow RL, Townsend DJ, Brinker EA, Charles NC (1993). "Periocular xanthogranulomas associated with severe adult-onset asthma". Trans Am Ophthalmol Soc 91: 99–125. PMC 1298462. PMID 8140711. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1298462.
- ^ Salam MT, Islam T, Gilliland FD (January 2008). "Recent evidence for adverse effects of residential proximity to traffic sources on asthma". Curr Opin Pulm Med 14 (1): 3–8. doi:10.1097/MCP.0b013e3282f1987a. PMID 18043269. http://journals.lww.com/co-pulmonarymedicine/Fulltext/2008/01000/Recent_evidence_for_adverse_effects_of_residential.3.aspx.
- ^ Liu AH (2004). "Something old, something new: indoor endotoxin, allergens and asthma". Paediatr Respir Rev 5 (Suppl A): S65–71. doi:10.1016/S1526-0542(04)90013-9. PMID 14980246.
- ^ Harju TH, Leinonen M, Nokso-Koivisto J, et al. (2006). "Pathogenic bacteria and viruses in induced sputum or pharyngeal secretions of adults with stable asthma". Thorax 61 (7): 579–84. doi:10.1136/thx.2005.056291. PMC 2104650. PMID 16517571. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2104650.
- ^ a b c d Gold DR,Wright R; Wright, R (2005). "Population disparities in asthma". Annu Rev Public Health 26: 89–113. doi:10.1146/annurev.publhealth.26.021304.144528. PMID 15760282.
- ^ Chen E, Miller GE (2007). "Stress and inflammation in exacerbations of asthma". Brain Behav Immun. 21 (8): 993–9. doi:10.1016/j.bbi.2007.03.009. PMC 2077080. PMID 17493786. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2077080.
- ^ O'Rourke ST (October 2007). "Antianginal actions of beta-adrenoceptor antagonists". Am J Pharm Educ 71 (5): 95. PMC 2064893. PMID 17998992. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2064893.
- ^ GINA 2009, p.6
- ^ GINA 2009, p.56
- ^ "California Children's Health Study". http://www.arb.ca.gov/research/chs/chs.htm.
- ^ Murk, W; Risnes, KR, Bracken, MB (2011 Jun). "Prenatal or early-life exposure to antibiotics and risk of childhood asthma: a systematic review.". Pediatrics 127 (6): 1125–38. PMID 21606151.
- ^ Droste, JH; Wieringa MH, Weyler JJ, Nelen VJ et al. (November 2000). "Does the use of antibiotics in early childhood increase the risk of asthma and allergic disease?". Clinical and Experimental Allergy 30 (11): 1547–1553. PMID 11069562.
- ^ Bufford, JD; Gern JE (May 2005). "The hygiene hypothesis revisited". Immunology and Allergy Clinics of North America 25 (2): 247–262. doi:10.1016/j.iac.2005.03.005. PMID 15878454.
- ^ BTS 2009 p.72
- ^ Dales R, Raizenne M (2004). "Residential exposure to volatile organic compounds and asthma". J Asthma 41 (3): 259–70. doi:10.1081/JAS-120026082. PMID 15260458.
- ^ Rumchev K, Spickett J, Bulsara M, et al. (April 2004). "Association of domestic exposure to volatile organic compounds with asthma in young children". Thorax 59 (9): 746–751. doi:10.1136/thx.2003.013680.
- ^ Jeong-Hee Kim,1 Ja-Kyoung Kim,1 Byong-Kwan Son, (April 2005). "Effects of Air Pollutants on Childhood Asthma". Yonsei Med J. 46 (2): 239–244. doi:10.3349/ymj.2005.46.2.239. PMC 2823020. PMID 15861497. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2823020.
- ^ Lehmann I, Rehwagen M, Diez U, (2001). "Enhanced in vivo IgE production and T cell polarization toward the type 2 phenotype in association with indoor exposure to VOC: results of the LARS study". International Journal of Hygiene and Environmental Health 204 (4): 211–221. doi:10.1078/1438-4639-00100. PMID 11833293.
- ^ Harving H, Dahl R, Mølhave L. (October 1991). "Lung function and bronchial reactivity in asthmatics during exposure to volatile organic compounds". Am Rev Respir Dis. 143 (4): 751–4. PMID 2008987.
- ^ D Norbäck, E Björnsson, C Janson, et al. (October 1995). "Asthmatic symptoms and volatile organic compounds, formaldehyde, and carbon dioxide in dwellings". Occup Environ Med 52 (6): 388–395. doi:10.1136/oem.52.6.388. PMC 1128243. PMID 7627316. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1128243.
- ^ Wieslander G, Norbäck D, Björnsson E, et al. (1997). "Asthma and the indoor environment: the significance of emission of formaldehyde and volatile organic compounds from newly painted indoor surfaces". Int Arch Occup Environ Health 69 (2): 115–24. PMID 9001918.
- ^ Wieslander G, Norbäck D, Edling C, (1996). "Airway symptoms among house painters in relation to exposure to volatile organic compounds (vocs)—a longitudinal study". The Annals of Occupational Hygiene 41 (2): 155–166. doi:10.1093/annhyg/41.2.155. PMID 9155237.
- ^ "Asthma Triggers: Gain Control - Nitrogen Dioxide". Environmental Protection Agencry. http://www.epa.gov/asthma/no2.html. Retrieved 11/10/11.
- ^ Barbara Kolarik,Kiril Naydenov, Malin Larsson, (October 2008). "The Association between Phthalates in Dust and Allergic Diseases among Bulgarian Children". Environ Health Perspect 116 (1): 98–103. doi:10.1289/ehp.10498. PMC 2199301. PMID 18197306. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2199301.
- ^ Oeie, L. Hersoug, L.-G. Madsen, J. O. (1997). "Residential Exposure to Plasticizers and Its Possible Role in the Pathogenesis of Asthma". Environ Health Perspect 105 (9): 972–978. doi:10.1289/ehp.97105972. ISSN 0091-6765. PMC 1470354. PMID 9374082. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1470354.
- ^ Jaakkola JJ, Knight TL. (July 2008). "The role of exposure to phthalates from polyvinyl chloride products in the development of asthma and allergies: a systematic review and meta-analysis". Environ Health Perspect 116 (7): 845–53. doi:10.1289/ehp.10846. PMC 2453150. PMID 18629304. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2453150.
- ^ C-G Bornehag, B Lundgren, C J. Weschler, et al (October 2005). "Phthalates in Indoor Dust and Their Association with Building Characteristics". Environ Health Perspect. 113 (10): 1399–1404. doi:10.1289/ehp.7809. PMC 1281287. PMID 16203254. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1281287.
- ^ O'Rourke ST; Ieromnimon, A; Jaakkola, MS (March 2006). "Interior Surface Materials and Asthma in Adults: A Population-based Incident Case-Control Study". American Journal of Epidemiology 164 (8): 742–749. doi:10.1093/aje/kwj249. PMID 16877535.
- ^ a b c Ober C,Hoffjan S; Hoffjan, S (2006). "Asthma genetics 2006: the long and winding road to gene discovery". Genes Immun 7 (2): 95–100. doi:10.1038/sj.gene.6364284. PMID 16395390.
- ^ Bouzigon E, Corda E, Aschard H, et al. (October 2008). "Effect of 17q21 Variants and Smoking Exposure in Early-Onset Asthma". The New England journal of medicine 359 (19): 1985. doi:10.1056/NEJMoa0806604. PMID 18923164.
- ^ a b Martinez FD (2007). "CD14, endotoxin, and asthma risk: actions and interactions". Proc Am Thorac Soc 4 (3): 221–5. doi:10.1513/pats.200702-035AW. PMC 2647622. PMID 17607003. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2647622.
- ^ a b c d Baxi SN, Phipatanakul W (April 2010). "The role of allergen exposure and avoidance in asthma". Adolesc Med State Art Rev 21 (1): 57–71, viii–ix. PMC 2975603. PMID 20568555. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2975603.
- ^ Asthma definition Mayo Clinic. Retrieved on 2010-02-08
- ^ Ramsey, CD; Celedón JC (January 2005). "The hygiene hypothesis and asthma". Current Opinion in Pulmonary Medicine 11 (1): 14–20. doi:10.1097/01.mcp.0000145791.13714.ae. PMID 15591883.
- ^ de Lara, C; Noble A (June 2007). "Dishing the dirt on asthma: What we can learn from poor hygiene". Biologics 1 (2): 139–150. PMC 2721305. PMID 19707324. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2721305.
- ^ Strachan DP (1989). "Hay fever, hygiene, and household size". BMJ 299 (6710): 1259–60. doi:10.1136/bmj.299.6710.1259. PMC 1838109. PMID 2513902. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1838109.
- ^ Von Mutius E, Martinez FD, Fritzsch C, et al. (1994). "Skin test reactivity and number of siblings". BMJ 308 (6930): 692–5. PMC 2539417. PMID 8142793. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2539417.
- ^ Jarvis D, Chinn S, Luczynska C, Burney P (1997). "The association of family size with atopy and atopic disease". Clin Exp Allergy 27 (3): 240–5. doi:10.1111/j.1365-2222.1997.tb00701.x. PMID 9088649.
- ^ Ball TM, Castro-Rodriguez JA, Griffith KA, et al. (2000). "Siblings, day-care attendance, and the risk of asthma and wheezing during childhood". N Engl J Med 343 (8): 538–543. doi:10.1056/NEJM200008243430803. PMID 10954761.
- ^ Pattemore PK, Johnston SL, Bardin PG (1992). "Viruses as precipitants of asthma symptoms. I Epidemiology". Clin Exp Allergy 22 (3): 325–336. doi:10.1111/j.1365-2222.1992.tb03094.x. PMID 1586873.
- ^ Nicholson KG, Kent J, Ireland DC (1993). Respiratory viruses and exacerbations of asthma in adults. 307. pp. 982–996. PMC 1679193. PMID 8241910. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1679193.
- ^ Tan WC, Xiang X, Qiu D, et al. (2003). "Epidemiology of respiratory viruses in patients hospitalized with near-fatal asthma, acute exacerbations of asthma, or chronic obstructive pulmonary disease". Am J Med 115 (4): 272–7. doi:10.1016/S0002-9343(03)00353-X. PMID 12967691.
- ^ Weiss ST, Tager IB, Munoz A, Speizer FE (1985). "The relationship of respiratory infections in early childhood to the occurrence of increased levels of bronchial responsiveness and atopy". Am Rev Respir Dis 131 (4): 573–8. PMID 3994151.
- ^ Illi S, von Mutius E, Lau S, et al. (2001). "Early childhood infectious diseases and the development of asthma up to school age: A birth cohort study". BMJ 322 (7283): 390–5. doi:10.1136/bmj.322.7283.390. PMC 26566. PMID 11179155. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=26566.
- ^ "WHO | Asthma". Who.int. 2008-06-03. http://www.who.int/mediacentre/factsheets/fs307/en/. Retrieved 2010-04-16.
- ^ "Patient/Public Education: Fast Facts — Asthma Demographics/Statistics". American Academy of Allergy Asthma & Immunology. http://www.aaaai.org/patients/resources/fastfacts/asthma_demographics.stm. Retrieved 2006-05-02.
- ^ Environmental Protection Agency. "Cockroaches and Pests — Indoor Environmental Asthma Triggers". Environmental Protection Agency. http://www.epa.gov/asthma/pests.html. Retrieved 23 November 2009.
- ^ a b National Center for Health Statistics (7 April 2006). "Asthma Prevalence, Health Care Use and Mortality, 2002". Centers for Disease Control and Prevention. http://www.cdc.gov/nchs/data/hestat/asthma/asthma.htm.
- ^ National Heart, Lung, and Blood Institute (May 2004). Morbidity & Mortality: 2004 Chart Book On Cardiovascular, Lung, and Blood Diseases. National Institutes of Health.
- ^ Pinnock H, Shah R (2007). "Asthma". BMJ 334 (7598): 847–50. doi:10.1136/bmj.39140.634896.BE. PMC 1853223. PMID 17446617. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1853223.
- ^ a b c d e f g National Asthma Education and Prevention Program (NAEPP). Expert panel report 3: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Heart, Lung, and Blood Institute; 2007.http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf
- ^ a b Sapp J and Niven AS (April 7, 2008). "Making the most of pulmonary function testing in the diagnosis of asthma". Journal of Respiratory Diseases. http://www.consultantlive.com/asthma/article/1145425/1404762.
- ^ "'Be in control' pack" (PDF). Asthma UK. http://www.asthma.org.uk/document.rm?id=29. Retrieved 2007-11-19.
- ^ deShazo RD and Stupko JE (October 1, 2008). "Diagnosing asthma in seniors: An algorithmic approach". Journal of Respiratory Diseases. http://www.consultantlive.com/asthma/article/1145425/1405157.
- ^ Gibson PG, McDonald VM, Marks GB (September 2010). "Asthma in older adults". Lancet 376 (9743): 803–13. doi:10.1016/S0140-6736(10)61087-2. PMID 20816547.
- ^ Hargreave, FE; Parameswaran K (August 2006). "Asthma, COPD and bronchitis are just components of airway disease". European Respiratory Journal 28 (2): 264–267. doi:10.1183/09031936.06.00056106. PMID 16880365. http://erj.ersjournals.com/cgi/content/full/28/2/264.
- ^ Diaz, P. Knoell. "Applied Therapeutics: The Clinical Use of Drugs, 9th Edition" Philadelphia: Lippincott Williams & Wilkins, 2009. Chapter 23 (Chronic Obstructive Pulmonary Disease)
- ^ a b NHLBI 2007 p.184-185
- ^ Tippets B Guilbert TW (2009). "Managing Asthma in Children, Part 2: Achieving and Maintaining Control". Consultant for Pediatricians 8 (6). http://pediatrics.consultantlive.com/display/article/1145470/1418640.
- ^ NHLBI 2007, p.213
- ^ "British Guideline on the Management of Asthma" (PDF). Scottish Intercollegiate Guidelines Network. 2008. http://www.sign.ac.uk/pdf/sign101.pdf. Retrieved 2008-08-04.
- ^ Thomson NC, Spears M (2005). "The influence of smoking on the treatment response in patients with asthma". Curr Opin Allergy Clin Immunol 5 (1): 57–63. doi:10.1097/00130832-200502000-00011. PMID 15643345.
- ^ NHLBI 2007, p.213
- ^ Rodrigo GJ, Nannini LJ (2006). "Comparison between nebulized adrenaline and beta2 agonists for the treatment of acute asthma. A meta-analysis of randomized trials". Am J Emerg Med 24 (2): 217–22. doi:10.1016/j.ajem.2005.10.008. PMID 16490653.
- ^ NHLBI 2007 p.351
- ^ a b c d NHLBI 2007 p.560
- ^ NHLBI 2007 p.218
- ^ a b c Fanta CH (March 2009). "Asthma". New England Journal of Medicine 360 (10): 1002–14. doi:10.1056/NEJMra0804579. PMID 19264689.
- ^ Cates CJ, Lasserson TJ, Jaeschke R (2009). Cates, Christopher J. ed. "Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events". Cochrane Database Syst Rev (3): CD006922. doi:10.1002/14651858.CD006922.pub2. PMID 19588410.
- ^ Cates CJ, Cates MJ (2008). Cates, Christopher J. ed. "Regular treatment with salmeterol for chronic asthma: serious adverse events". Cochrane Database Syst Rev (3): CD006363. doi:10.1002/14651858.CD006363.pub2. PMID 18646149.
- ^ "FDA sees asthma drug risks — Yahoo! News". http://news.yahoo.com/s/nm/20081205/hl_nm/us_drugs_asthma_1. Retrieved December 5, 2008. [dead link]
- ^ NHLBI 2007 p.250
- ^ Wang JJ, Rochtchina E, Tan AG, Cumming RG, Leeder SR, Mitchell P (April 2009). "Use of inhaled and oral corticosteroids and the long-term risk of cataract". Ophthalmology 116 (4): 652–7. doi:10.1016/j.ophtha.2008.12.001. PMID 19243828.
- ^ Dahl R (August 2006). "Systemic side effects of inhaled corticosteroids in patients with asthma". Respir Med 100 (8): 1307–17. doi:10.1016/j.rmed.2005.11.020. PMID 16412623.
- ^ Nishimura J, Ikuyama S (2000). "Glucocorticoid-induced osteoporosis: pathogenesis and management". J Bone Miner Metab 18 (6): 350–2. doi:10.1007/s007740070008. PMID 11052469.
- ^ a b c Rodrigo GJ, Rodrigo C, Hall JB (2004). "Acute asthma in adults: a review". Chest 125 (3): 1081–102. doi:10.1378/chest.125.3.1081. PMID 15006973.
- ^ Noppen, M. (August 2002). "Magnesium Treatment for Asthma : Where Do We Stand?". Chest 122 (2): 396–8. doi:10.1378/chest.122.2.396. PMID 12171805.
- ^ a b NHLBI 2007 p.373
- ^ NHLBI 2007 p.399
- ^ a b Castro, M; Musani, AI, Mayse, ML, Shargill, NS (2010 Apr). "Bronchial thermoplasty: a novel technique in the treatment of severe asthma.". Therapeutic advances in respiratory disease 4 (2): 101–16. PMID 20435668.
- ^ Blanc PD, Trupin L, Earnest G, Katz PP, Yelin EH, Eisner MD (2001). "Alternative therapies among adults with a reported diagnosis of asthma or rhinosinusitis : data from a population-based survey". Chest 120 (5): 1461–7. doi:10.1378/chest.120.5.1461. PMID 11713120.
- ^ Shenfield G, Lim E, Allen H (2002). "Survey of the use of complementary medicines and therapies in children with asthma". J Paediatr Child Health 38 (3): 252–7. doi:10.1046/j.1440-1754.2002.00770.x. PMID 12047692.
- ^ Kaur, B; Rowe BH, Arnold E (2009). Arnold, Elizabeth. ed. "Vitamin C supplementation for asthma". Cochrane Database Syst Rev (1): CD000993. doi:10.1002/14651858.CD000993.pub3. PMID 19160185.
- ^ a b NHLBI 2007 p.240
- ^ McCarney RW, Brinkhaus B, Lasserson TJ, Linde K (2004). McCarney, Robert W. ed. "Acupuncture for chronic asthma". Cochrane Database Syst Rev (1): CD000008. doi:10.1002/14651858.CD000008.pub2. PMID 14973944.
- ^ Blackhall K, Appleton S, Cates CJ (2003). Blackhall, Karen. ed. "Ionisers for chronic asthma". Cochrane Database Syst Rev (3): CD002986. doi:10.1002/14651858.CD002986. PMID 12917939.
- ^ PC Gøtzsche, HK Johansen (2008). Gøtzsche, Peter C. ed. "House dust mite control measures for asthma". Cochrane Database Syst Rev (2): CD001187. doi:10.1002/14651858.CD001187.pub3. PMID 18425868.
- ^ Recer GM (February 2004). "A review of the effects of impermeable bedding encasements on dust-mite allergen exposure and bronchial hyper-responsiveness in dust-mite-sensitized patients". Clin Exp Allergy 34 (2): 268–75. doi:10.1111/j.1365-2222.2004.01863.x. PMID 14987307. http://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0954-7894&date=2004&volume=34&issue=2&spage=268.
- ^ Hondras MA, Linde K, Jones AP (2005). Hondras, Maria A. ed. "Manual therapy for asthma". Cochrane Database Syst Rev (2): CD001002. doi:10.1002/14651858.CD001002.pub2. PMID 15846609.
- ^ "www.sign.ac.uk" (PDF). May 2008. p. 37. http://www.sign.ac.uk/pdf/sign101.pdf.
- ^ Maddox L, Schwartz DA (2002). "The pathophysiology of asthma". Annu. Rev. Med. 53: 477–98. doi:10.1146/annurev.med.53.082901.103921. PMID 11818486.
- ^ Beckett PA, Howarth PH (2003). "Pharmacotherapy and airway remodelling in asthma?". Thorax 58 (2): 163–74. doi:10.1136/thorax.58.2.163. PMC 1746582. PMID 12554904. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1746582.
- ^ NHLBI 2007, p.1
- ^ "WHO Disease and injury country estimates". World Health Organization. 2009. http://www.who.int/healthinfo/global_burden_disease/estimates_country/en/index.html. Retrieved November 11, 2009.
- ^ "World Health Organization Fact Sheet Fact sheet No 307: Asthma". 2009. http://www.who.int/mediacentre/factsheets/fs307/en/print.html. Retrieved 2 September 2010.
- ^ Braman SS (July 2006). "The global burden of asthma". Chest 130 (Suppl): 4S–12S. doi:10.1378/chest.130.1_suppl.4S. PMID 16840363.
- ^ a b Lazarus SC (August 2010). "Clinical practice. Emergency treatment of asthma". N. Engl. J. Med. 363 (8): 755–64. doi:10.1056/NEJMcp1003469. PMID 20818877.
- ^ a b "Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee". Lancet 351 (9111): 1225–32. April 1998. doi:10.1016/S0140-6736(97)07302-9. PMID 9643741.
- ^ World Health Organization. "WHO: Asthma". http://www.who.int/mediacentre/factsheets/fs307/en/. Retrieved 2007-12-29.
- ^ Ng'ang'a LW, Odhiambo JA, Mungai MW, et al. (November 1998). "Prevalence of exercise induced bronchospasm in Kenyan school children: An urban-rural comparison". Thorax 53 (11): 919–26. doi:10.1136/thx.53.11.919. PMC 1745121. PMID 10193388. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1745121.
- ^ Waite DA, Eyles EF, Tonkin SL, O'Donnell TV (January 1980). "Asthma prevalence in Tokelauan children in two environments". Clin Allergy 10 (1): 71–5. doi:10.1111/j.1365-2222.1980.tb02082.x. PMID 7363447.
- ^ Anderson, HR; Gupta R, Strachan DP, Limb ES (January 2007). "50 years of asthma: UK trends from 1955 to 2004". Thorax 62 (1): 85–90. doi:10.1136/thx.2006.066407. PMC 2111282. PMID 17189533. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2111282.
- ^ Getahun D, Demissie K, Rhoads GG (2005). "Recent trends in asthma hospitalization and mortality in the United States". Journal of asthma 42 (5): 373–8. doi:10.1081/JAS-62995. PMID 16036412.
- ^ a b NHLBI 2007, p.1
- ^ Hayden, Merrill (19 September 2009). "Asthma Guide". http://www.webmd.com/asthma/guide/how-we-breath.
- ^ Corbett, Sara (March/April 2005). "The Asthma Trap". Mother Jones. http://motherjones.com/print/16323.
- ^ Simpson CR, Sheikh A (2010). "Trends in the epidemiology of asthma in England: a national study of 333,294 patients". J R Soc Med 103 (3): 98–106. doi:10.1258/jrsm.2009.090348. PMID 20200181.
- ^ Grant EN, Wagner R, Weiss KB (August 1999). "Observations on emerging patterns of asthma in our society". J Allergy Clin Immunol 104 (2 Pt 2): S1–S9. doi:10.1016/S0091-6749(99)70268-X. PMID 10452783.
- ^ Anandan C, Nurmatov U, van Schayck OC, Sheikh A (February 2010). "Is the prevalence of asthma declining? Systematic review of epidemiological studies". Allergy 65 (2): 152–67. doi:10.1111/j.1398-9995.2009.02244.x. PMID 19912154.
- ^ World Health Organization (2007) (PDF). Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. pp. 15–20, 49. ISBN 9789241563468. http://www.who.int/gard/publications/GARD_Manual/en/index.html. Retrieved 2010-05-14.
- ^ Centers for Disease Control and Prevention (CDC). Vital signs: asthma prevalence, disease characteristics, and self-management education --- United States, 2001--2009. MMWR Morb Mortal Wkly Rep 2011; 60:547.
- ^ Centers for Disease Control and Prevention (CDC). Vital signs: asthma prevalence, disease characteristics, and self-management education --- United States, 2001--2009. MMWR Morb Mortal Wkly Rep 2011; 60:547.
- ^ Lara M, Akinbami L, Flores G,Morgenstern H (2006). "Heterogeneity of childhood asthma among Hispanic children: Puerto Rican children bear a disproportionate burden". Pediatrics 117 (1): 43–53. doi:10.1542/peds.2004-1714. PMID 16396859.
- ^ Davis AM, Kreutzer R, Lipsett M, King G,Shaikh N (2006). "Asthma prevalence in Hispanic and Asian American ethnic subgroups: results from the California Healthy Kids Survey". Pediatrics 118 (2): e363–70. doi:10.1542/peds.2005-2687. PMID 16882779.
- ^ Johnson DB, Oyama N, LeMarchand L,Wilkens L (2004). "Native Hawaiians mortality, morbidity, and lifestyle: comparing data from 1982, 1990, and 2000". Pac Health Dialog 11 (2): 120–30. PMID 16281689.
- ^ Naqvi M, Thyne S, Choudhry S "et al." (2007). "Ethnic-specific differences in bronchodilator responsiveness among african americans, puerto ricans, and mexicans with asthma". J Asthma 44 (8): 639–48. doi:10.1080/02770900701554441. PMID 17943575.
- ^ Burchard EG, Avila PC, Nazario S "et al." (2004). "Lower bronchodilator responsiveness in Puerto Rican than in Mexican subjects with asthma". Am J Respir Crit Care Med 169 (3): 386–92. doi:10.1164/rccm.200309-1293OC. PMID 14617512.
- ^ Gold DR,Acevedo-Garcia D; Acevedo-Garcia, D (2005). "Immigration to the United States and acculturation as risk factors for asthma and allergy". J Allergy Clin Immunol 116 (1): 38–41. doi:10.1016/j.jaci.2005.04.033. PMID 15990770.
- ^ Eldeirawi KM,Persky VW; Persky, VW (2006). "Associations of acculturation and country of birth with asthma and wheezing in Mexican American youths". J Asthma 43 (4): 279–86. doi:10.1080/0277090060022869. PMID 16809241.
- ^ Bush A, Menzies-Gow A (December 2009). "Phenotypic differences between pediatric and adult asthma". Proc Am Thorac Soc 6 (8): 712–9. doi:10.1513/pats.200906-046DP. PMID 20008882.
- ^ a b Opolski M, Wilson I (September 2005). "Asthma and depression: a pragmatic review of the literature and recommendations for future research". Clin Pract Epidemol Ment Health 1: 18. doi:10.1186/1745-0179-1-18. PMC 1253523. PMID 16185365. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1253523.
- ^ Thorowgood JC (November 1873). "On Bronchial Asthma". British Medical Journal 2 (673): 600. doi:10.1136/bmj.2.673.600. PMC 2294647. PMID 20747287. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2294647.
- ^ Gaskoin G (March 1872). "On the Treatment of Asthma". British Medical Journal 1 (587): 339. doi:10.1136/bmj.1.587.339. PMC 2297349. PMID 20746575. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2297349.
- ^ Berkart JB (June 1880). "The Treatment of Asthma". British Medical Journal 1 (1016): 917–8. doi:10.1136/bmj.1.1016.917. PMC 2240555. PMID 20749537. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2240555.
- ^ Berkart JB (June 1880). "The Treatment of Asthma". British Medical Journal 1 (1017): 960–2. doi:10.1136/bmj.1.1017.960. PMC 2240530. PMID 20749546. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2240530.
- ^ Bosworth FH (1886). "Hay Fever, Asthma, and Allied Affections". Transactions of the Annual Meeting of the American Climatological Association 2: 151–70. PMC 2526599. PMID 21407325. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2526599.
- ^ Doig RL (February 1905). "Epinephrin; Especially in Asthma". California State Journal of Medicine 3 (2): 54–5. PMC 1650334. PMID 18733372. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1650334.
- ^ Matthews C (February 1910). "The use of adrenalin in acute asthma". British Medical Journal 1 (2564): 441. doi:10.1136/bmj.1.2564.441. PMC 2330484. PMID 20764937. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2330484.
- "Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma" (PDF). National Heart Lung and Blood Institute. 2007. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf.
- "British Guideline on the Management of Asthma" (pdf). British Thoracic Society. 2009. http://www.brit-thoracic.org.uk/Portals/0/Clinical%20Information/Asthma/Guidelines/sign101%20revised%20June%2009.pdf.
- "Global Initiative for Asthma". 2009. http://www.ginasthma.org/Guidelineitem.asp??l1=2&l2=1&intId=1561.
Cardiopulmonary therapy DiagnosticPulmonary function testing • Polysomnography Disease Therapy See also Pathology of respiratory system (J, 460–519), respiratory diseases Upper RT
Common cold)Headvocal folds: Laryngopharyngeal reflux (LPR) · Vocal fold nodule · Vocal cord paresis · Vocal cord dysfunction
Lower RT/lung disease
(including LRTIs)acute: Acute bronchitischronic: COPD (Chronic bronchitis, Acute exacerbations of chronic bronchitis, Acute exacerbation of COPD, Emphysema) · Asthma (Status asthmaticus, Aspirin-induced, Exercise-induced) · BronchiectasisInterstitial/
restrictiveBy pathogenBy vector/routeBy distributionBroncho- · LobarOther
Other/general Immune disorders: hypersensitivity and autoimmune diseases (279.5–6) Type I/allergy/atopy
(T-cells)ForeignAllergic contact dermatitis · Mantoux testAutoimmune
Wikimedia Foundation. 2010.